Your browser doesn't support javascript.
loading
Impact of cerebrospinal fluid matrix on the detection of Alzheimer's disease with Aß42 and influence of disease on the total-Aß42/Aß40 ratio.
Slemmon, J Randall; Shapiro, Alice; Mercken, Marc; Streffer, Johannes; Romano, Gary; Andreasen, Niels; Zetterberg, Henrik; Blennow, Kaj.
Afiliação
  • Slemmon JR; Neurosciences Biomarkers, Janssen Pharmaceutical Companies, Raritan, New Jersey, USA.
  • Shapiro A; Neurosciences Biomarkers, Janssen Pharmaceutical Companies, Raritan, New Jersey, USA.
  • Mercken M; Neurosciences Discovery, Janssen Pharmaceutical Companies, Beerse, Belgium.
  • Streffer J; Experimental Medicine, Janssen Pharmaceutical Companies, Beerse, Belgium.
  • Romano G; Neuroscience Therapeutic Area, Janssen Research and Development, Titusville, New Jersey, USA.
  • Andreasen N; Memory clinic, M51, Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Stockholm, Sweden.
  • Zetterberg H; Institute of Neurology, University College London, Queen Square, London, UK.
  • Blennow K; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
J Neurochem ; 135(5): 1049-58, 2015 Dec.
Article em En | MEDLINE | ID: mdl-26332787
ABSTRACT
The 42-amino acid fragment of amyloid ß (Aß1-42) in cerebrospinal fluid has continued to be important for detecting cerebral ß-amyloidosis in Alzheimer's disease (AD). However, there are impediments to our ability to fully understand this measurement, including matrix interference and changes linked to apolipoprotein E (APOE) ε4 genotype. This study investigated matrix interference as a contributing factor for detecting AD in APOE ε4-negative patients by comparing total extractable Aß1-42 to free Aß1-42. It also examined the ratio of total Aß1-42 to Aß1-40, since changes relative to other Aß peptides may provide a measurement of cerebral ß-amyloidosis that is neutral to changes in APP metabolism. Total Aß1-42 lost the diagnostic power for detecting AD, confirming a role for matrix in the diagnostic. However, when total Aß1-42/Aß1-40 was examined, the separation between groups was reestablished. This result was confirmed in a second sample set of unknown APOE status. These results confirmed that matrix interference in some cerebrospinal fluid samples appears to contribute to identifying AD patients and this can be compensated by using a total extracted Aß1-42/Aß1-40 ratio when matrix interference is small. It may be preferable to employ a total Aß1-42/Aß1-40 measurement, since this could minimize variability because of matrix and compensate for across patient differences. Aß1-42 measurement in CSF has provided an important tool for early detection of AD. However, it appears that most assays measure a free fraction of Aß1-42. This study examined total extracted Aß1-42, since this would provide a more accurate assessment of Aß1-42 in AD CSF. Total Aß1-42 measurements alone were not good for detecting AD but total Aß1-42/Aß1-40 performed well.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fragmentos de Peptídeos / Peptídeos beta-Amiloides / Doença de Alzheimer Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fragmentos de Peptídeos / Peptídeos beta-Amiloides / Doença de Alzheimer Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article